(MENAFN- IMARC Group)
IMARC Group, a leading market research company, has recently releases report titled
“Preclinical Imaging Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2024-2032, ” The study provides a detailed analysis of the industry, including the global
preclinical imaging market size, share, trends, and growth forecasts. The report also includes competitor and regional analysis and highlights the latest advancements in the market.
Report Highlights:
How big is the preclinical imaging market ?
The global preclinical imaging market size reached US$ 3.8 Billion in
2023. Looking forward, IMARC Group expects the market to reach US$ 5.0 Billion by
2032, exhibiting a growth rate (CAGR) of 2.97% during
2024-2032.
What is a Preclinical Imaging?
Preclinical imaging refers to the use of various imaging techniques and technologies to visualize and study biological processes, diseases, and drug responses in living organisms before clinical trials in humans. This field is primarily focused on research and development (R&D) in the pharmaceutical, biotechnology, and academic sectors. Preclinical imaging techniques include Magnetic Resonance Imaging (MRI), Computed Tomography (CT), Positron Emission Tomography (PET), Single Photon Emission Computed Tomography (SPECT), Ultrasound, and Optical Imaging. Additionally, preclinical imaging aids in the understanding of disease mechanisms, which can lead to more targeted and effective treatments.
Request for a sample copy of this report:
https://www.imarcgroup.com/preclinical-imaging-market/requestsample
What are the growth prospects and trends in the preclinical imaging industry?
The pharmaceutical industry's continuous focus on research and development (R&D) fuels the demand for preclinical imaging technologies which represents one of the key factors driving the growth of the market across the globe. The escalating costs and risks associated with drug development are leading to a greater emphasis on preclinical studies to identify promising candidates and avoid costly failures in later stages. Ongoing advancements in preclinical imaging technologies, such as high-resolution MRI, PET, and optical imaging, enhance researchers' ability to visualize and analyze biological processes, thus making these methods more attractive for drug development. The rising global burden of chronic diseases like cancer and cardiovascular conditions necessitates effective preclinical research. Preclinical imaging aids in understanding disease mechanisms and testing potential treatments. The shift towards personalized medicine requires a deeper understanding of individual variations in drug responses. Preclinical imaging plays a crucial role in this by providing insights into patient-specific drug effects. Investments by governments and research institutions in preclinical imaging infrastructure and research projects are stimulating the market growth across the globe.
What is included in market segm entation?
The report has segmented the market into the following categories:
Breakup by Product:
Modality Optical Imaging Systems Preclinical Nuclear Imaging Systems Micro-Ultrasound Systems Micro-MRI Systems Micro-CT Systems Preclinical Photoacoustic Imaging Systems Preclinical Magnetic Particle Imaging (MPI) Systems
Reagent Preclinical Optical Imaging Systems Preclinical Nuclear Imaging Reagents Preclinical MRI Contrast Agents Preclinical Ultrasound Contrast Agents Preclinical CT Contrast Agents
Service
Breakup by End Use:
Biotech Companies Pharmaceutical Companies Research Institutes
Market Breakup by Region:
North America (United States, Canada) Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others) Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others) Latin America (Brazil, Mexico, Others) Middle East and Africa
If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.
About Us:
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC's information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company's expertise.
Contact US:
IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email:
Tel No:(D) +91 120 433 0800
United States: +1-631-791-1145 | United Kingdom: +44-753-713-2163
MENAFN15032024004122016232ID1107981452
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.